About dātma
dātma is a company based in Beaverton (United States) founded in 2016 by Kemal Sonmez, Christopher Corless, and Ganapati Srinivasa. dātma has raised $2.5 million across 4 funding rounds from investors including National Science Foundation. dātma offers products and services including datma.FED, datma.BASE, and datma.360. dātma operates in a competitive market with competitors including Strand Life Sciences, Genuity Science, ICarbonX, Cellworks and Omega Therapeutics, among others.
- Headquarter Beaverton, United States
- Founders Kemal Sonmez, Christopher Corless, Ganapati Srinivasa
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Omics Data Automation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$2.5 M (USD)
in 4 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
Dec 17, 2024
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of dātma
dātma offers a comprehensive portfolio of products and services, including datma.FED, datma.BASE, and datma.360.
Secure platform for sharing healthcare data between labs and companies.
System for ingesting and harmonizing multimodal healthcare data.
Tool for consolidating and analyzing healthcare data sources.
People of dātma
Unlock access to complete
Unlock access to complete
Funding Insights of dātma
dātma has successfully raised a total of $2.5M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $2.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $2.5M
-
First Round
First Round
(01 Jul 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Seed - dātma | Valuation |
investors |
|
| Feb, 2019 | Amount | Grant - dātma | Valuation |
investors |
|
| Aug, 2018 | Amount | Grant - dātma | Valuation |
investors |
Investors in dātma
dātma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Founded Year | Domain | Location |
Investments & Acquisitions by dātma
Financial Statements - dātma
Dātma Comparisons
Competitors of dātma
dātma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Strand Life Sciences, Genuity Science, ICarbonX, Cellworks and Omega Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| domain | founded_year | HQ Location |
AI-based omics data analysis solutions are provided to researchers.
|
|
| domain | founded_year | HQ Location |
Bioinformatics platforms are provided for health management and drug development.
|
|
| domain | founded_year | HQ Location |
Biosimulation platform developed for therapeutic design in life sciences.
|
|
| domain | founded_year | HQ Location |
Platform for human genome study is provided for precision medicine.
|
|
| domain | founded_year | HQ Location |
Integrated genomic analysis platform for epigenome data is provided.
|
Latest news on Dātma
Frequently Asked Questions about dātma
dātma was founded in 2016 and raised its 1st funding round 1 year after it was founded.
dātma is headquartered in Beaverton, United States. It is registered at Beaverton, Oregon, United States.
Noah Nasser is the current CEO of dātma.
dātma is a funded company, having raised a total of $2.5M across 4 funding rounds to date. The company's 1st funding round was a Grant of $1.59M, raised on Jul 01, 2017.
dātm was founded in 2016 and is based in Beaverton, United States. Tools are offered by the company in the precision medicine sector to support clinics with data harmonization, visualization, sharing, and analysis. Omics data automation is enabled through products including dātm.BASE, dātm.360, and dātm.FED, bridging research applications to clinical use. Operations focus on software solutions for healthcare decision support.
dātma's top competitors include Strand Life Sciences, Omega Therapeutics and Cellworks.
dātma offers datma.FED, datma.BASE, and datma.360.
dātma has 1 investor. Key investors include National Science Foundation.